Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) at Chughtai Lab

Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) at Chughtai Lab

Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) at Chughtai Lab is a highly specialized molecular and hematological diagnostic investigation designed to identify female carriers of Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency). Hemophilia A and B are X-linked recessive bleeding disorders caused by mutations in the F8 and F9 genes, respectively. Because these genes are located on the X chromosome, males who inherit the abnormal gene will manifest the disease, while females who inherit one mutated allele are typically asymptomatic carriers. However, identifying carrier status is of paramount clinical importance for family planning, prenatal diagnosis, and managing potential bleeding risks in carriers themselves.

This advanced diagnostic service at Chughtai Lab utilizes state-of-the-art molecular biology techniques, including polymerase chain reaction (PCR), gene sequencing, and multiplex ligation-dependent probe amplification (MLPA), alongside precise coagulation factor assays. The inclusion of ‘Form NIBD’ signifies a structured clinical and laboratory protocol, often coordinated with the National Institute of Blood Diseases, ensuring that comprehensive clinical history, family pedigree mapping, and informed genetic consent are meticulously documented prior to testing. This collaborative and systematic approach ensures the highest level of diagnostic accuracy and clinical utility for patients across Pakistan, including major hubs like Lahore, Karachi, and Islamabad.

Understanding your carrier status provides vital information about the likelihood of passing a hemophilia gene mutation to your children. Furthermore, due to a physiological process known as lyonization (random X-chromosome inactivation), some female carriers may have significantly reduced levels of Factor VIII or Factor IX, putting them at risk for easy bruising, prolonged bleeding after dental extractions, or severe hemorrhage during surgical procedures and childbirth. This test serves as a cornerstone for personalized medical management and comprehensive genetic counseling.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the integrity of the genetic and biochemical analyses. Patients undergoing Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) at Chughtai Lab should observe the following guidelines:

• Documentation and Consent: Patients must complete and sign the specialized Form NIBD. This includes providing a detailed family history, a pedigree chart if available, and formal informed consent for genetic testing.
• Medical History: Inform the laboratory staff of any personal history of bleeding disorders, recent blood transfusions, or administration of clotting factor concentrates, as these can temporarily alter biochemical factor assay results.
• Medication Review: Disclose all current medications, especially anticoagulants (like warfarin, heparin, or direct oral anticoagulants) and antiplatelet drugs, which may affect clotting assays. Do not stop any prescribed medication unless explicitly instructed by your physician.
• Dietary Restrictions: Fasting is generally not required for molecular (DNA) testing. However, a light, non-fatty meal is recommended prior to sample collection if coagulation factor assays are to be performed concurrently.
• Hydration: Stay well-hydrated by drinking plenty of water before the venipuncture, as this makes blood collection easier and safer.

During the Procedure

The sample collection process is conducted by highly trained phlebotomists at Chughtai Lab, adhering to strict aseptic techniques and international safety standards:

• Patient Identification: The phlebotomist will verify the patient’s identity using at least two identifiers and cross-check the details with the completed Form NIBD.
• Venipuncture: The patient will be seated comfortably. A tourniquet will be applied to the upper arm to locate a suitable vein, typically in the antecubital fossa. The skin will be thoroughly cleansed with an antiseptic solution.
• Sample Collection: A sterile, single-use needle will be inserted into the vein. For genetic (DNA) analysis, blood is collected in an EDTA (purple-top) tube. If clotting factor activity assays are also ordered, a buffered sodium citrate (light blue-top) tube will be filled. Precise filling of the sodium citrate tube is critical to maintain the correct blood-to-anticoagulant ratio.
• Post-Collection Care: The needle is gently removed, and immediate pressure is applied to the puncture site with a sterile gauze pad to prevent hematoma formation. A bandage will be applied once bleeding has stopped. Due to potential mild bleeding tendencies in carriers, pressure may need to be held longer than usual.
• Duration and Experience: The entire venipuncture procedure takes less than 5 to 10 minutes. Patients may feel a brief pinch or sting as the needle enters the skin, but the procedure is generally well-tolerated and safe.

When is a Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) Performed?

Family History of Hemophilia

Physicians strongly recommend this test for women who have a confirmed family history of Hemophilia A or B. This includes daughters of hemophilic fathers (who are obligate carriers), mothers of an affected child, and sisters, maternal aunts, or nieces of an affected individual. Identifying carrier status helps map the inheritance pattern within the family.

Preconception and Prenatal Planning

For couples planning a family where the woman has a known or suspected family history of hemophilia, this test is crucial. Knowing carrier status prior to pregnancy allows couples to receive comprehensive genetic counseling, understand the genetic risks to future offspring, and explore reproductive options, including pre-implantation genetic diagnosis (PGD) or prenatal diagnostic testing.

Unexplained Bleeding Tendencies in Females

While hemophilia primarily affects males, female carriers can experience bleeding symptoms if their factor levels are low due to skewed X-chromosome inactivation. Women presenting with unexplained easy bruising, frequent epistaxis (nosebleeds), heavy menstrual bleeding (menorrhagia), or prolonged bleeding after minor surgeries or dental work are candidates for this evaluation.

Maternal Lineage Risk Assessment

When a male child is newly diagnosed with Hemophilia A or B without a prior family history, genetic testing of the mother is essential. This determines whether the child’s condition arose from a de novo (new) mutation or if the mother is a carrier, which has significant implications for her future pregnancies and the health of her female relatives.

Confirmation of Genetic Status for Family Counseling

In families where a specific genetic mutation in the F8 or F9 gene has already been identified in an affected male relative, targeted carrier testing is performed for female relatives. This highly specific testing confirms or rules out the presence of the exact familial mutation, providing definitive answers and reducing anxiety for non-carrier family members.

What Does a Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) Detect?

The Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) at Chughtai Lab is designed to detect a wide array of genetic and biochemical markers associated with hemophilia carrier status. The comprehensive diagnostic panel evaluates and detects:

• F8 Gene Intron 22 Inversion: The most common genetic mutation causing severe Hemophilia A, accounting for nearly 45% of cases.
• F8 Gene Intron 1 Inversion: Another significant recurrent inversion mutation responsible for approximately 1-5% of severe Hemophilia A cases.
• F8 Gene Point Mutations: Single nucleotide changes, including missense mutations (altering a single amino acid) and nonsense mutations (creating a premature stop codon).
• F8 Gene Frameshift Mutations: Small insertions or deletions (indels) that disrupt the reading frame of the gene, leading to a non-functional Factor VIII protein.
• F8 Gene Large Deletions or Duplications: Significant structural variations involving one or more exons of the F8 gene.
• F9 Gene Point Mutations: Nucleotide substitutions across the promoter, coding exons, and splice junctions of the Factor IX gene, associated with Hemophilia B.
• F9 Gene Deletions and Insertions: Micro-deletions, micro-insertions, or large gene deletions that eliminate or severely alter the Factor IX protein structure.
• F9 Leyden Mutation: A specific mutation in the F9 gene promoter that causes severe childhood deficiency but improves after puberty due to hormonal influences.
• Factor VIII Clotting Activity (FVIII:C): Biochemical measurement of functional Factor VIII in the plasma, which can be reduced in carriers.
• Factor IX Clotting Activity (FIX:C): Biochemical measurement of functional Factor IX in the plasma, helping to identify carriers with low factor levels.
• Skewed X-Chromosome Inactivation (Lyonization): Assessment of whether the active X chromosome preferentially carries the mutated allele, explaining low factor levels in carriers.
• Pathogenic Variants: Genetic alterations with established scientific evidence linking them to Hemophilia A or B.
• Likely Pathogenic Variants: Genetic changes highly likely to cause the disease based on structural and clinical data.
• Variants of Uncertain Significance (VUS): Genetic alterations where clinical significance cannot yet be determined, requiring further familial studies.
• Benign and Likely Benign Variants: Normal genetic variations that do not affect factor production or function.
• Heterozygous Carrier Status: Confirmation that a female possesses one normal allele and one mutated allele of the F8 or F9 gene.
• Homozygous or Compound Heterozygous Status: Extremely rare cases where a female inherits two mutated alleles, resulting in clinical hemophilia.
• Familial Mutation Match: Precise identification of the exact mutation previously documented in an affected male relative.
• DNA Sequence Homology: Comparison of the patient’s genetic sequence against standard reference genomes to identify novel mutations.
• Coagulation Pathway Integrity: Indirect assessment of the intrinsic clotting pathway through specialized coagulation profiling.

Turnaround Time and Report Access at Chughtai Lab

Because Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) involves complex molecular genetic sequencing and specialized coagulation assays, the turnaround time is longer than routine blood tests. Typically, genetic sequencing and mutation analysis results are completed within 3 to 4 weeks, depending on the complexity of the specific mutations being analyzed. Coagulation factor activity assays, if performed separately, may be available sooner.

Chughtai Lab ensures a seamless and highly confidential reporting process. Once the specialized pathologists and geneticists finalize the report, patients receive an automated SMS notification. Reports can be securely accessed and downloaded online via the official Chughtai Lab website or through the user-friendly Chughtai Lab Mobile App. Given the genetic implications of the findings, patients are strongly encouraged to share these results with a qualified hematologist or genetic counselor for comprehensive interpretation and guidance.

Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
F8 Gene Mutation Analysis	No pathogenic mutations, inversions, or deletions detected.	Detection of Intron 22 or Intron 1 inversion, or other pathogenic F8 mutations (confirms Hemophilia A carrier).
F9 Gene Mutation Analysis	No pathogenic mutations, deletions, or promoter variants detected.	Detection of pathogenic point mutations, deletions, or insertions in the F9 gene (confirms Hemophilia B carrier).
Factor VIII Clotting Activity (FVIII:C)	50% to 150% of normal activity.	Decreased activity (typically 30% to 50%), indicating carrier status with skewed lyonization and potential mild bleeding risk.
Factor IX Clotting Activity (FIX:C)	50% to 150% of normal activity.	Decreased activity (typically 30% to 50%), indicating carrier status with skewed lyonization and potential mild bleeding risk.
Gene Copy Number (MLPA)	Normal diploid copy number of all exons in F8 and F9 genes.	Detection of heterozygous deletion or duplication of one or more exons, confirming carrier status.
Form NIBD Clinical Correlation	Pedigree and genetic data show no risk of familial hemophilia transmission.	Pedigree and genetic data confirm high risk of transmission; indicates necessity for genetic counseling.
X-Chromosome Inactivation Pattern	Balanced inactivation of maternal and paternal X chromosomes (approx. 50:50).	Highly skewed inactivation (e.g., >80:20) favoring expression of the mutated allele, explaining clinical bleeding symptoms.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Carrier Identification for Factor VIII and Factor IX Deficiency (Form NIBD)?

• Experienced Healthcare Professionals: Our team includes highly qualified molecular pathologists, geneticists, and hematologists specializing in hereditary bleeding disorders.
• Patient-Focused Care: We prioritize patient comfort, privacy, and clear communication throughout the genetic testing journey.
• Quality Diagnostic Services: Chughtai Lab adheres to rigorous international quality control standards, ensuring highly accurate and reproducible genetic results.
• Professional Reporting: Detailed and comprehensive diagnostic reports that clearly explain genetic variants and biochemical findings.
• Modern Diagnostic Approach: Utilizing cutting-edge PCR, MLPA, and DNA sequencing technologies to detect even the rarest genetic mutations.
• Comfortable Environment: Our state-of-the-art collection centers across Pakistan offer a welcoming and stress-free environment for patients.
• Convenient Location: With an extensive network of labs and collection points in Lahore, Karachi, Islamabad, and beyond, access to testing is highly convenient.
• Commitment to Accurate Diagnosis: Dedicated to providing precise answers that empower families and clinicians to make informed medical and reproductive decisions.